Eli Lilly Impresses with Study Data on Foundayo and Retatrutide – Stock Rises Over 4%!
Reading Time: 3 minutes
The FDA approval for Foundayo as the first GLP-1 pill without fasting requirements is also convincing for women in every stage of menopause. The triple-agonist Retatrutide led to weight loss of up to 28.3% in Phase 3 studies and alleviated osteoarthritis. The first quarter impressed with a revenue increase of 56%, primarily driven by Mounjaro and Zepbound. The stock is trading at an all-time high. Eli Lilly (LLY) achieved a significant operational milestone on April 1 with the FDA approval of Foundayo (Orforglipron)....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
